| 臺大學術典藏 |
2022-01-11T06:49:41Z |
Increased risk of glomerulonephritis and chronic kidney disease in relation to the severity of psoriasis, concomitant medication, and comorbidity: A nationwide population-based cohort study
|
HSIEN-YI CHIU; Huang H.-L.; Li C.-H.; Yin Y.-J.; Chen H.-A.; Hsu S.-T.; Lin S.-J.; Tsai T.-F.; Ho S.-Y. |
| 臺大學術典藏 |
2022-01-11T06:49:40Z |
The association between clinical response to ustekinumab and immunogenicity to ustekinumab and prior adalimumab
|
HSIEN-YI CHIU; Chu T.W.; Cheng Y.-P.; Tsai T.-F. |
| 臺大學術典藏 |
2022-01-11T06:49:40Z |
Correlation of IL36RN mutation with different clinical features of pustular psoriasis in Chinese patients
|
Wang T.-S.; HSIEN-YI CHIU; Hong J.-B.; Chan C.-C.; Lin S.-J.; Tsai T.-F. |
| 臺大學術典藏 |
2022-01-11T06:49:39Z |
Concomitant sleep disorders significantly increase the risk of cardiovascular disease in patients with psoriasis
|
HSIEN-YI CHIU; Hsieh C.-F.; Chiang Y.-T.; Tsai Y.-W.; Huang W.-F.; Li C.-Y.; Wang T.-S.; Tsai T.-F. |
| 臺大學術典藏 |
2022-01-11T06:49:38Z |
The risk of chronic pancreatitis in patients with psoriasis: A population-based cohort study
|
HSIEN-YI CHIU; Hsieh C.-F.; Chiang Y.-T.; Huang W.-F.; Tsai T.-F. |
| 臺大學術典藏 |
2022-01-11T06:49:38Z |
Risk of fractures in vitiligo patients treated with phototherapy-A retrospective population-based cohort study
|
Lo P.-C.; Li C.-Y.; Huang W.-F.; Tsai Y.-W.; Liu H.-N.; Chang Y.-T.; HSIEN-YI CHIU; Tsai T.-F. |
| 臺大學術典藏 |
2022-01-11T06:49:38Z |
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study
|
HSIEN-YI CHIU; Tsai T.-F. |
| 臺大學術典藏 |
2022-01-11T06:49:37Z |
The impact of long-term secukinumab treatment on Epstein–Barr virus and cytomegalovirus loads in patients with psoriasis
|
HSIEN-YI CHIU; Chan C.-C.; Tsai T.-F. |
| 臺大學術典藏 |
2022-01-11T06:49:37Z |
Increased risk of aortic aneurysm (AA) in relation to the severity of psoriasis: A national population-based matched-cohort study
|
HSIEN-YI CHIU; Lo P.-C.; Huang W.-F.; Tsai Y.-W.; Tsai T.-F. |
| 臺大學術典藏 |
2022-01-11T06:49:36Z |
Secukinumab in psoriasis patients with prior ustekinumab treatment: Results of a single-center experience
|
Wang T.-S.; Chan C.-C.; HSIEN-YI CHIU; Tsai T.-F. |
| 臺大學術典藏 |
2022-01-11T06:49:35Z |
An investigator-initiated, open-label, single-center, proof-of-concept-study of omalizumab in patients with poorly controlled acute urticaria
|
HSIEN-YI CHIU; Chan C.-C.; Chu C.-Y.; Tsai T.-F. |
| 臺大學術典藏 |
2022-01-11T06:49:35Z |
Increased risk of avascular necrosis in patients with psoriatic disease: A nationwide population-based matched cohort study
|
HSIEN-YI CHIU; Wang I.-T.; Huang W.-F.; Tsai Y.-W.; Shiu M.-N.; Tsai T.-F. |
| 臺大學術典藏 |
2022-01-11T06:49:34Z |
Risk of varicocele in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic disease: a population-based case–control study
|
HSIEN-YI CHIU; Wang I.-T.; Huang W.-F.; Tsai Y.-W.; Tsai T.-F. |
| 臺大學術典藏 |
2022-01-11T06:49:34Z |
Serial QuantiFERON-TB Gold testing in patients with psoriasis treated with ustekinumab
|
Hsiao C.-Y.; HSIEN-YI CHIU; Wang T.-S.; Tsai T.-F. |
| 臺大學術典藏 |
2022-01-11T06:49:33Z |
Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: A multicentric prospective cohort study
|
HSIEN-YI CHIU; Hui R.C.-Y.; Huang Y.-H.; Huang R.-Y.; Chen K.-L.; Tsai Y.-C.; Lai P.-J.; Wang T.-S.; Tsai T.-F. |
| 臺大學術典藏 |
2022-01-11T06:49:32Z |
Risk of Psoriasis Following Terbinafine or Itraconazole Treatment for Onychomycosis: A Population-Based Case-Control Comparative Study
|
HSIEN-YI CHIU; Chang W.-L.; Tsai T.-F.; Tsai Y.-W.; Shiu M.-N. |
| 臺大學術典藏 |
2022-01-11T06:49:31Z |
Psoriasis in Taiwan: From epidemiology to new treatments
|
HSIEN-YI CHIU; Wang T.-S.; Chen P.-H.; Hsu S.-H.; Tsai Y.-C.; Tsai T.-F. |
| 臺大學術典藏 |
2022-01-11T06:49:30Z |
Psoriasis is associated with a greater risk for cardiovascular procedure and surgery in patients with hypertension: A nationwide cohort study
|
HSIEN-YI CHIU; Chang W.-L.; Shiu M.-N.; Huang W.-F.; Tsai T.-F. |
| 臺大學術典藏 |
2022-01-11T06:49:30Z |
Human leukocyte antigen and demographic characteristics in Chinese patients with active peripheral type psoriatic arthritis who had inadequate response to conventional disease-modifying antirheumatic drugs in a single dermatologic clinic
|
Sin C.-Z.; Wang T.-S.; HSIEN-YI CHIU; Tsai T.-F. |
| 臺大學術典藏 |
2022-01-11T06:49:29Z |
Prevalence, clinical features and treatment pattern of patients with concurrent diagnoses of rheumatoid arthritis and psoriatic disease: results of a 14-year retrospective study in a tertiary referral center
|
Chen K.-L.; HSIEN-YI CHIU; Lin J.-H.; Ye J.-D.; Cho Y.-H.; Li K.-J.; Tsai T.-F. |
| 臺大學術典藏 |
2022-01-11T06:49:29Z |
Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement
|
Ger T.-Y.; Huang Y.-H.; Hui R.C.-Y.; Tsai T.-F.; HSIEN-YI CHIU |
| 臺大學術典藏 |
2022-01-11T06:49:28Z |
Clinical Features and Genetic Polymorphism in Chinese Patients with Erythrodermic Psoriasis in a Single Dermatologic Clinic
|
Lo Y.; HSIEN-YI CHIU; Tsai T.-F. |
| 臺大學術典藏 |
2022-01-11T06:49:28Z |
The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies
|
Wu C.-Y.; HSIEN-YI CHIU; Tsai T.-F. |
| 臺大學術典藏 |
2022-01-11T06:49:28Z |
Gut Microbiome in Psoriasis is Perturbed Differently During Secukinumab and Ustekinumab Therapy and Associated with Response to Treatment
|
Yeh N.-L.; Hsu C.-Y.; Tsai T.-F.; HSIEN-YI CHIU |
| 臺大學術典藏 |
2022-01-11T06:49:27Z |
National trends in incidence, mortality, hospitalizations, and expenditures for pemphigus in Taiwan
|
HSIEN-YI CHIU; Chang C.J.; Lin Y.J.; Tsai T.-F. |
